Immuno-Oncology Therapy Market Size, Share, Growth Report 2032

Immuno-Oncology Therapy Market

Immuno-Oncology Therapy Market By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Others), Therapeutic Area (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, and Others Cancers), By End-user ( Hospitals, Clinics, Ambulatory Surgical Centers (ASC’s), and Cancer Research Institutes): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-2534 Published Date: Jul-2021 Status : Published

The global Immuno-oncology therapy market accounted for USD 62.2 Billion in 2020 and is expected to reach USD 194.9 Billion by 2028, growing at a CAGR of around 15% between 2021 and 2028.

Market Overview

The global Immuno-oncology therapy market accounted for USD 62.2 Billion in 2020 and is expected to reach USD 194.9 Billion by 2028, growing at a CAGR of around 15% between 2021 and 2028.       

Immuno-oncology or cancer immunotherapy also called as biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology to offer improved treatments. Healthcare providers are focusing on improving treatments and reduction in recurrence of cancer post-chemotherapy. This has pushed the growth of the immuno-oncology therapy market globally.

Request Free Sample

COVID-19 Impact Analysis:

The global Immuno-oncology therapy market has witnessed a slight decline in the sales for short term to the lockdown enforcement placed by governments in order to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production, resulting in a disruption across the whole supply chain.   

The major reason for decline in market during pandemic outbreak was decrease in patient volume in hospitals, owing to rescheduling and delaying of procedures for safety reasons. Furthermore, delays happened after careful review of patient history and if feasible, healthcare providers rescheduled endoscopic procedures to minimize risk of getting exposed to COVID-19 during hospital visits. All these factors negatively impacted the Immuno-oncology therapy market in 2020.

Growth Factors

Rising R&D in cancer immunotherapy is resulting in the introduction of advanced treatment options that are more effective and efficient. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market growth. Introduction of new drugs has resulted in an increase in the competitive rivalry. Immuno modulatory drugs, such as thalidomide, lenalidomide, and pomalidomide, were the best treatment options available in the past few years. Introduction of newer drug classes, such as monoclonal antibodies and HDAC inhibitors, designed to target receptors related to multiple myeloma, is expected to initiate newer trends in the market.

Ongoing studies on similar drugs designed to minimize side effects are expected to propel the market for these drug classes in the immuno-oncology therapy market.

Report Scope:

Request Free Sample

Segment Analysis Preview

The immuno-oncology therapy market is segmented on the basis of therapy type into monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, cancer vaccines and others. Immune checkpoint inhibitors are further segmented into PD1/ PDL1 and CTLA-4. Monoclonal antibodies segment is expected to grow at the fastest rate in the global market over the forecast period.

Based on the therapeutic area, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Breast cancer segment is expected to grow at the fastest rate in the global market over the forecast period.

Hospitals, clinics, ambulatory surgical centers and cancer research institutes are the key end-user segments of the global immuno-oncology therapy market. The hospital's segment dominated the market in terms of revenue in 2020.

Request Free Sample

Region Analysis Preview  

North America, Europe, Asia-Pacific, Latin America and Middle East & Africa are key regional segments of global immuno-oncology therapy market. North America is anticipated to remain the leading region over the forecast period. Rising incidence of the disease, increasing ease of access to modern therapeutics coupled with expanding geriatric population is propelling the market in this region. On the other hand, factors, such as challenges in clinical trials, coupled with higher costs and rapidly changing reimbursement policies, are impeding the growth of the market in this region. The Asia Pacific is anticipated to show a very high, favorable growth rate in cancer immunotherapy adoption. Rising incidence of the disease and, in turn, rising mortality rate is propelling demand for immunotherapy in the region. Moreover, the presence of market players with major investments in the market, such as AstraZeneca and Pfizer, Inc., is boosting the market in the Asia Pacific.

Request Free Sample

Key Market Players & Competitive Landscape

The major players operating in the immuno-oncology therapy market are Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals among others.

The global Immuno-oncology therapy market is segmented as follows:   

By Therapy Type

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • PD1/ PDL1
  • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Others

By Therapeutic Area

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Other Cancers

By  End-user

  •  Hospitals
  •  Clinics
  •  Ambulatory Surgical Centers (ASC’s)
  • Cancer Research Institutes

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

The global Immuno-oncology therapy market was valued at USD 62.2 Billion in 2020.

The global Immuno-oncology therapy market is expected to reach USD 194.9 Billion by 2028, growing at a CAGR of 15% between 2021 to 2028.

Some of the key factors driving the global Immuno-oncology therapy market growth are rising R&D in cancer immunotherapy and a paradigm shift from traditional chemotherapies to immunotherapies.

North America is anticipated to remain the leading region over the forecast period. Rising incidence of the disease, increasing ease of access to modern therapeutics coupled with expanding geriatric population is propelling the market in this region.

The major players operating in the immuno-oncology therapy market are Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals among others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed